PL397167A1 - Przeciwnowotworowe bialko fuzyjne - Google Patents

Przeciwnowotworowe bialko fuzyjne

Info

Publication number
PL397167A1
PL397167A1 PL397167A PL39716711A PL397167A1 PL 397167 A1 PL397167 A1 PL 397167A1 PL 397167 A PL397167 A PL 397167A PL 39716711 A PL39716711 A PL 39716711A PL 397167 A1 PL397167 A1 PL 397167A1
Authority
PL
Poland
Prior art keywords
domain
fusion protein
amino acid
sequence
fragment
Prior art date
Application number
PL397167A
Other languages
English (en)
Inventor
Jerzy Szczepan Pieczykolan
Sebastian Dominik Pawlak
Bartłomiej Żerek
Michał Szymanik
Anna Maria Pieczykolan
Piotr Kamil Rózga
Urszula Marta Szawłowska
Albert Robert Jaworski
Małgorzata Izabela Teska-Kamińska
Original Assignee
Adamed Spólka Z Ograniczona Odpowiedzialnoscia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adamed Spólka Z Ograniczona Odpowiedzialnoscia filed Critical Adamed Spólka Z Ograniczona Odpowiedzialnoscia
Priority to PL397167A priority Critical patent/PL397167A1/pl
Priority to MX2014006369A priority patent/MX2014006369A/es
Priority to CA2856480A priority patent/CA2856480A1/en
Priority to PCT/IB2012/056806 priority patent/WO2013080147A2/en
Priority to US14/361,279 priority patent/US20150044162A1/en
Priority to HK15102260.2A priority patent/HK1201727A1/xx
Priority to JP2014544020A priority patent/JP2015500228A/ja
Priority to EA201491049A priority patent/EA201491049A1/ru
Priority to CN201280058346.6A priority patent/CN103974711A/zh
Priority to SG11201402312WA priority patent/SG11201402312WA/en
Priority to IN4498CHN2014 priority patent/IN2014CN04498A/en
Priority to EP12816127.0A priority patent/EP2785362A2/en
Priority to BR112014012808A priority patent/BR112014012808A2/pt
Priority to AU2012345494A priority patent/AU2012345494A1/en
Priority to KR1020147018001A priority patent/KR20140097529A/ko
Publication of PL397167A1 publication Critical patent/PL397167A1/pl
Priority to PH12014501083A priority patent/PH12014501083A1/en
Priority to IL232743A priority patent/IL232743A0/en
Priority to ZA2014/04667A priority patent/ZA201404667B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Wynalazek dotyczy dziedziny terapeutycznych bialek fuzyjnych, zwlaszcza rekombinowanych bialek fuzyjnych. Bialko fuzyjne zawiera domene (a), która jest funkcjonalny fragment sekwencji bialka hTRAIL rozpoczynajacy sie aminokwasem w pozycji nie nizszej niz hTRAIL95, i konczacy sie aminokwasem hTRAIL281, lub homolog wspomnianego funkcjonalnego fragmentu hTRAIL o sekwencji aminokwasów przynajmniej w 85% identycznej z tym fragmentem; i przynajmniej jedna domene (b) stanowiaca sekwencje peptydu efektorowego o dzialaniu hamujacym synteze bialka wewnatrz komórki, przy czym sekwencja domeny (b) jest przylaczona na C-koncu i/lub N-koncu domeny (a), bialko fuzyjne nie posiada domeny wiazacej sie z receptorami weglowodanowymi na powierzchni komórki. Bialko fuzyjne znajduje zastosowania w leczeniu chorób nowotworowych.
PL397167A 2011-11-28 2011-11-28 Przeciwnowotworowe bialko fuzyjne PL397167A1 (pl)

Priority Applications (18)

Application Number Priority Date Filing Date Title
PL397167A PL397167A1 (pl) 2011-11-28 2011-11-28 Przeciwnowotworowe bialko fuzyjne
SG11201402312WA SG11201402312WA (en) 2011-11-28 2012-11-28 Anticancer fusion protein
IN4498CHN2014 IN2014CN04498A (pl) 2011-11-28 2012-11-28
PCT/IB2012/056806 WO2013080147A2 (en) 2011-11-28 2012-11-28 Anticancer fusion protein
US14/361,279 US20150044162A1 (en) 2011-11-28 2012-11-28 Anticancer fusion protein
HK15102260.2A HK1201727A1 (en) 2011-11-28 2012-11-28 Anticancer fusion protein
JP2014544020A JP2015500228A (ja) 2011-11-28 2012-11-28 抗がん融合タンパク質
EA201491049A EA201491049A1 (ru) 2011-11-28 2012-11-28 Противораковый слитый белок
CN201280058346.6A CN103974711A (zh) 2011-11-28 2012-11-28 抗癌融合蛋白
MX2014006369A MX2014006369A (es) 2011-11-28 2012-11-28 Proteina de fusion anticancerigena.
CA2856480A CA2856480A1 (en) 2011-11-28 2012-11-28 Anticancer fusion protein
EP12816127.0A EP2785362A2 (en) 2011-11-28 2012-11-28 Anticancer fusion protein
BR112014012808A BR112014012808A2 (pt) 2011-11-28 2012-11-28 proteína de fusão anticâncer
AU2012345494A AU2012345494A1 (en) 2011-11-28 2012-11-28 Anticancer fusion protein
KR1020147018001A KR20140097529A (ko) 2011-11-28 2012-11-28 항암 융합 단백질
PH12014501083A PH12014501083A1 (en) 2011-11-28 2014-05-14 Anticancer fusion protein
IL232743A IL232743A0 (en) 2011-11-28 2014-05-21 anticancer fusion protein
ZA2014/04667A ZA201404667B (en) 2011-11-28 2014-06-25 Anticancer fusion protein

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL397167A PL397167A1 (pl) 2011-11-28 2011-11-28 Przeciwnowotworowe bialko fuzyjne

Publications (1)

Publication Number Publication Date
PL397167A1 true PL397167A1 (pl) 2013-06-10

Family

ID=47561689

Family Applications (1)

Application Number Title Priority Date Filing Date
PL397167A PL397167A1 (pl) 2011-11-28 2011-11-28 Przeciwnowotworowe bialko fuzyjne

Country Status (18)

Country Link
US (1) US20150044162A1 (pl)
EP (1) EP2785362A2 (pl)
JP (1) JP2015500228A (pl)
KR (1) KR20140097529A (pl)
CN (1) CN103974711A (pl)
AU (1) AU2012345494A1 (pl)
BR (1) BR112014012808A2 (pl)
CA (1) CA2856480A1 (pl)
EA (1) EA201491049A1 (pl)
HK (1) HK1201727A1 (pl)
IL (1) IL232743A0 (pl)
IN (1) IN2014CN04498A (pl)
MX (1) MX2014006369A (pl)
PH (1) PH12014501083A1 (pl)
PL (1) PL397167A1 (pl)
SG (1) SG11201402312WA (pl)
WO (1) WO2013080147A2 (pl)
ZA (1) ZA201404667B (pl)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014141094A1 (en) 2013-03-14 2014-09-18 Adamed Sp. Z O.O. Anticancer conjugate

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101990341B1 (ko) 2013-03-12 2019-06-19 몰레큘러 템플레이츠, 인코퍼레이션. 세포 내재화를 유도하기 위한 ｃｄ20-결합 면역독소 및 이의 사용 방법
JP6655017B2 (ja) 2014-01-27 2020-02-26 モレキュラー テンプレーツ, インク.Molecular Templates, Inc. Ｍｈｃクラスｉエピトープ送達ポリペプチド
EP3502134B1 (en) * 2014-03-11 2020-12-16 Molecular Templates, Inc. Proteins comprising binding regions, shiga toxin a subunit effector regions, and carboxy-terminal, endoplasmic reticulum localization signal motifs
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
EP3137488B1 (en) * 2014-06-11 2019-01-02 Molecular Templates, Inc. Protease-cleavage resistant, shiga toxin a subunit effector polypeptides and cell-targeting molecules comprising the same
WO2016126950A1 (en) 2015-02-05 2016-08-11 Molecular Templates, Inc. Multivalent cd20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof
US10428132B2 (en) 2015-02-11 2019-10-01 West China Hospital, Sichuan University Tumor necrosis factor-related apoptosis-inducing ligand variant, as well as a preparation method and use thereof
LT3303373T (lt) 2015-05-30 2020-07-10 Molecular Templates, Inc. Deimunizuoto shiga toksino a subvieneto karkasai ir juos apimančios ląstelės taikinio molekulės
CN112574316A (zh) * 2015-07-02 2021-03-30 博际生物医药科技(杭州)有限公司 用于肿瘤靶向治疗的白细胞介素-15融合蛋白
KR101732126B1 (ko) 2015-11-05 2017-05-02 한국생명공학연구원 췌장암 치료용 융합 단백질 및 이의 용도
PL233352B1 (pl) * 2016-09-15 2019-10-31 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Przeciwnowotworowe białko fuzyjne
IL302130A (en) 2016-12-07 2023-06-01 Molecular Templates Inc Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
CN106632680A (zh) * 2016-12-27 2017-05-10 上海交通大学 植物体系表达人源化抗agr2单克隆抗体18a4的质粒构建
KR102590672B1 (ko) 2017-01-25 2023-10-18 몰레큘러 템플레이츠, 인코퍼레이션. 탈면역된 시가 독소 a 서브유닛 이펙터 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자
JP2021515774A (ja) * 2018-03-06 2021-06-24 ザ・ジョンズ・ホプキンス・ユニバーシティ 制御性ｔ細胞を枯渇する薬剤、及びチェックポイント阻害剤を使用してがんを治療、又は予防する方法
CN110612117B (zh) 2018-04-17 2024-04-12 分子模板公司 包含去免疫化的志贺毒素a亚基支架的her2靶向分子
WO2020234498A2 (es) * 2019-05-15 2020-11-26 Universidad De Granada Terapia génica con los genes hokd y ldrb para el tratamiento del cáncer
CN113354738B (zh) * 2020-03-05 2022-09-09 绍兴德方华生物技术有限公司 融合毒素VEGF165b/mGEL及其编码基因与应用
US20230310557A1 (en) * 2020-08-17 2023-10-05 Atb Therapeutics Recombinant immunotoxin comprising a ribotoxin or rnase
CN114681599B (zh) * 2020-12-31 2024-07-02 中国科学院上海药物研究所 一种阳离子脂质体疫苗及其制备方法和用途
EP4382607A4 (en) * 2021-08-06 2025-11-19 Kao Corp NUCLEIC ACID STRUCTURE INVOLVING SNARE PROTEINS
CN117384859B (zh) * 2023-12-13 2024-03-22 北京翊博生物集团有限公司 一种树突状细胞来源的外泌体的制备方法及应用
CN118792375B (zh) * 2024-06-25 2025-09-23 华南农业大学 一种具有补肾壮阳功效的瓜蒌多肽及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2253753T3 (es) 1995-06-29 2006-06-01 Immunex Corporation Citocina que induce apoptosis.
WO2001060393A1 (en) 2000-02-16 2001-08-23 Bechtel Bwxt Idaho, Llc Selective destruction of cells infected with human immunodeficiency virus
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
CN1257187C (zh) * 2003-10-22 2006-05-24 上海恰尔生物技术有限公司 钙网蛋白－肿瘤坏死因子相关凋亡诱导配体的融合蛋白及其制法和用途
JP4688678B2 (ja) 2003-11-03 2011-05-25 北京沙東生物技術有限公司 抗癌作用を有する組換えタンパク質、それをコードする遺伝子、及びそれらの使用
US7252993B2 (en) 2004-03-12 2007-08-07 Battelle Energy Alliance, Llc Plasmids encoding therapeutic agents
EP1910407B1 (en) 2005-07-29 2011-09-14 The Government of the United States of America, as represented by the Secretary of Health and Human Services Mutated pseudomonas exotoxins with reduced antigenicity
PT1915626E (pt) 2005-08-16 2012-02-03 Genentech Inc Sensibilidade da apoptose a apo2l/trail por ensaio de expressão de galnac-t14 em células/tecidos
WO2008052322A1 (en) 2006-10-30 2008-05-08 Viventia Biotech Inc. Immunotoxγn fusions comprising an antibody fragment and a plant toxin linked by protease cleavable linkers
SG163558A1 (en) 2006-12-29 2010-08-30 Osprey Pharmaceuticals Usa Inc Methods of selecting and producing modified toxins, conjugates containing modified toxins and uses thereof
US20090131317A1 (en) 2007-06-22 2009-05-21 Affymax, Inc. Compounds and peptides that bind the trail receptor
GB0723059D0 (en) 2007-11-23 2008-01-02 Nat Univ Ireland Improved cytokine design
GB0724532D0 (en) 2007-12-17 2008-01-30 Nat Univ Ireland Trail variants for treating cancer
KR101863136B1 (ko) * 2008-01-24 2018-05-31 에스퍼란스 파마슈티컬스, 인코포레이티드 용해 도메인 융합 구성물 및 이를 제조하고 사용하는 방법
CL2009001191A1 (es) 2008-05-14 2010-07-02 Genentech Inc Uso del peptido apo2l/trail porque sirve para preparar un medicamento para tratar el cancer de pulmon y el linfoma de hodkin.
JP5475766B2 (ja) * 2008-06-30 2014-04-16 ユニバーシティ オブ ペンシルベニア Ｆｎ１４／ＴＲＡＩＬ融合タンパク質

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014141094A1 (en) 2013-03-14 2014-09-18 Adamed Sp. Z O.O. Anticancer conjugate

Also Published As

Publication number Publication date
SG11201402312WA (en) 2014-06-27
BR112014012808A2 (pt) 2019-09-24
WO2013080147A2 (en) 2013-06-06
US20150044162A1 (en) 2015-02-12
AU2012345494A1 (en) 2014-07-10
MX2014006369A (es) 2014-07-09
ZA201404667B (en) 2015-09-30
IN2014CN04498A (pl) 2015-09-11
KR20140097529A (ko) 2014-08-06
CN103974711A (zh) 2014-08-06
EA201491049A1 (ru) 2014-10-30
IL232743A0 (en) 2014-07-31
EP2785362A2 (en) 2014-10-08
CA2856480A1 (en) 2013-06-06
HK1201727A1 (en) 2015-09-11
JP2015500228A (ja) 2015-01-05
WO2013080147A3 (en) 2014-02-13
PH12014501083A1 (en) 2014-08-04

Similar Documents

Publication Publication Date Title
PL397167A1 (pl) Przeciwnowotworowe bialko fuzyjne
ES2676023T3 (es) Polipéptidos de IL-22 y proteínas de fusión de IL-22 Fc y métodos de uso
BR112015020587A2 (pt) proteínas de fusão de apelina e suas utilizações
EA201491277A1 (ru) Противораковый слитый белок
AU2015269210A8 (en) Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof
EA201400568A1 (ru) Альбуминсвязывающие антитела и их связывающие фрагменты
NZ784569A (en) Bispecific t cell engaging antibody constructs
MX377692B (es) Peptidos anti-inflamatorios y usos de los mismos.
BR112013013548B8 (pt) Proteína de fusão anticancerígena
MX2013015324A (es) Polipeptidos de fusion con domino de proteína ácida del suero, y métodos de uso de los mismos.
PL393578A1 (pl) Przeciwnowotworowe białko fuzyjne
EA201791238A1 (ru) Способы и композиции, в которых используются варианты полипептидов klotho
CL2017000200A1 (es) Célula huésped mejorada para producir proteinas
MX343386B (es) Proteinas de fusion portadoras de peptido como vacunas para alergia.
EP2403871A4 (en) FOR ABUSED PRION PROTEIN SPECIFIC ANTIBODIES AND EPITOPES
MX2019000529A (es) Proteina de suministro cerebral.
MX2025010859A (es) Polipéptidos de fusión dap10/dap12.
HRP20210635T1 (hr) Novi mutant humanog seruma albumina
NZ724196A (en) Uti fusion proteins
NZ706202A (en) Peptide antagonists of the vasopressin-2 receptor
BR112013011285A2 (pt) vacina
LV15035A (lv) Rekombinēta himēriska polipeptīda, kas satur melanokortīna otrā tipa receptoru (MC2R) un melanokortīnu receptoru palīgproteīnu (MRAP), kDNS secības, un tās izmantošana aktīvo vielu testēšanai un terapeitiskiem mērķiem
UA108911C2 (xx) Протираковий злитий протеїн
UY33043A (es) Proteinas de enlace de antigenos anti-orai 1 y usos de las mismas